dostarlimab
Combined Dostarlimab, Standard of Care Improves Survival for Endometrial Cancer Patients
Adding the programmed cell death protein-1 (PD-1) checkpoint inhibitor dostarlimab (Jemperli, GSK) to carboplatin ...
MAY 3, 2023
100% Remission Rate ‘Thrills’ Rectal Cancer Investigators
A phase 2 study of patients with early-stage rectal cancer, conducted at Memorial Sloan Kettering Cancer ...
JUNE 8, 2022
Load more